Month: September 2022

iPS IN OTHER DISEASES. "Although cells that release insulin in response to glucose can be produced, they appear very frail ... A similar story is found for human iPSC-derived cardiomyocytes that can definitely beat in the culture dish ... but do not display all of the expected phenotypes of mature cells." http://hmg.oxfordjournals.org/content/early/2013/08/19/hmg.ddt379.full View in LinkedIn

SHORT-LIVED STEM CELLS. "There is general acceptance that mesenchymal cells, cord blood, adipose tissues and other adult stem cell sources often do not survive for more than a few weeks in patients, and their effects are most likely through growth factor release, host inflammatory responses and vascular alterations rather than replacing tissues lost in the disease." http://hmg.oxfordjournals.org/content/early/2013/08/19/hmg.ddt379.full View in LinkedIn

POC: STEM CELLS CURE MOUSE EYE DISEASE. "Just last month a team of doctors ... reported how they had taken stem cells from mice embryos, “turned” them into photoreceptors in the lab and then used them to restore sight in adult mice." This is truly the start of space age medicine. http://stemcellstm.alphamedpress.org/site/misc/News159.xhtml View in LinkedIn

GROUNDBREAKING FIRST HUMAN iPS TRIAL. "World’s first induced pluripotent stem cells clinical study on humans launches in Japan. Earlier this year doctors announced success in restoring sight to a man suffering from macular degeneration by treating him with stem cells derived from human embryos." http://stemcellstm.alphamedpress.org/site/misc/News159.xhtml View in LinkedIn

iPS MAY BE AVAILABLE FOR MACULAR DEGENERATION IN JAPAN IN 5 YEARS, "It depends on the regulation in each country. However, it will not become in common use before 10 years. ( In Japan, by chance, it will be 5 years or so.)" http://lnkd.in/d98BEBz View in LinkedIn

JAPAN'S WORLD LEADERSHIP IN STEM CELLS has resulted in part from having a Nobel winner on the subject (Shinya Yamanaka MD PhD), but also by mobilization of investments and legal framework behind this remarkable innovation. The Innovation Network Corporation of Japan (INCJ), recently assembled a promising new company around the work. http://www.megakaryon.com/index-e.html View in LinkedIn

iPS FUTURE. "Right now it takes a lot of time, money, and labor to reprogram cells ... each intervention costs 20 million yen ($200,000) per eye and will take 10 people a year to complete ... The possibility of "allogeneic" treatment, in which iPS cells from one person could be used in many people, could reduce the cost tenfold." http://lnkd.in/d637hZz View in LinkedIn

CHANGING SKIN TO SPERM. "Scientists have turned skin tissue from infertile men into early-stage sperm cells in a groundbreaking study that raises hopes for new therapies for the condition. The unexpected success of the procedure has stunned some scientists, because it was thought to be impossible for the men to make any sperm." http://www.theguardian.com/science/2014/may/01/study-turns-skin-tissue-infertile-men-sperm-cells View in LinkedIn

TREATING BALDNESS. "This is the first time anyone has made scalable amounts of epithelial stem cells that are capable of generating the epithelial component of hair follicles." ... many potential applications, he adds, including wound healing, cosmetics, and hair regeneration." http://lnkd.in/dnSZBZ4 View in LinkedIn

IS THE iPS REAL LEGACY: REPROGRAMMING AGING? "Adult fibroblasts taken from patients with rapid aging diseases such as Progeria can also be reprogrammed to an embryonic state and look very similar to control iPSCs." http://lnkd.in/decTvtt View in LinkedIn